Update on the Colon Health and Life-Long Exercise Change Trial: A Phase III Study of the Impact of an Exercise Program on Disease-Free Survival in Colon Cancer Survivors

K.S. Courneya; J. Vardy; S. Gill; D. Jonker; P. O'Brien; C.M. Friedenreich; H. Dhillon; R.K.S. Wong; R.M. Meyer; J.J. Crawford; K.L. Campbell; H. Prapevessis; C. O'Callaghan; J. Turner; L.M. Spencer; H.P. van der Ploeg; D. Tu; C.M. Booth

doi:https://doi.org/10.1007/s11888-014-0231-8

Update on the Colon Health and Life-Long Exercise Change Trial: A Phase III Study of the Impact of an Exercise Program on Disease-Free Survival in Colon Cancer Survivors

K.S. Courneya, J. Vardy, S. Gill, D. Jonker, P. O'Brien, C.M. Friedenreich, H. Dhillon, R.K.S. Wong, R.M. Meyer, J.J. Crawford, K.L. Campbell, H. Prapevessis, C. O'Callaghan, J. Turner, L.M. Spencer, H.P. van der Ploeg, D. Tu, C.M. Booth

Public and occupational health (VUmc)

Research output: Contribution to journal › Article › Academic › peer-review

26 Citations (Scopus)

Abstract

The Colon Health and Life-Long Exercise Change (CHALLENGE) trial is evaluating the effects of a 3-year exercise program on disease-free survival in 962 patients with resected high-risk stage II or stage III colon cancer. The purpose of this commentary is to provide an update on the CHALLENGE trial. As of December 31, 2013, the trial had randomized 250 patients in 20 Canadian centers and 26 Australian centers, with further expansion planned. Early barriers to accrual are reported and strategies to improve accrual are discussed. Of the 250 patients randomized to date, 89 % have stage III colon cancer, 56 % were treated with leucovorin/5-fluorouracil/oxaliplatin-based chemotherapy, 58 % have a body mass index of at least 27.5 kg/m

Original language	English
Pages (from-to)	321-328
Journal	Current colorectal cancer reports
Volume	10
Issue number	3
DOIs	https://doi.org/10.1007/s11888-014-0231-8
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1007/s11888-014-0231-8

Cite this

Courneya, K. S., Vardy, J., Gill, S., Jonker, D., O'Brien, P., Friedenreich, C. M., Dhillon, H., Wong, R. K. S., Meyer, R. M., Crawford, J. J., Campbell, K. L., Prapevessis, H., O'Callaghan, C., Turner, J., Spencer, L. M., van der Ploeg, H. P., Tu, D., & Booth, C. M. (2014). Update on the Colon Health and Life-Long Exercise Change Trial: A Phase III Study of the Impact of an Exercise Program on Disease-Free Survival in Colon Cancer Survivors. Current colorectal cancer reports, 10(3), 321-328. https://doi.org/10.1007/s11888-014-0231-8

@article{08fc378bb5f1404a989b3b3ccd1e93a0,

title = "Update on the Colon Health and Life-Long Exercise Change Trial: A Phase III Study of the Impact of an Exercise Program on Disease-Free Survival in Colon Cancer Survivors",

abstract = "The Colon Health and Life-Long Exercise Change (CHALLENGE) trial is evaluating the effects of a 3-year exercise program on disease-free survival in 962 patients with resected high-risk stage II or stage III colon cancer. The purpose of this commentary is to provide an update on the CHALLENGE trial. As of December 31, 2013, the trial had randomized 250 patients in 20 Canadian centers and 26 Australian centers, with further expansion planned. Early barriers to accrual are reported and strategies to improve accrual are discussed. Of the 250 patients randomized to date, 89 % have stage III colon cancer, 56 % were treated with leucovorin/5-fluorouracil/oxaliplatin-based chemotherapy, 58 % have a body mass index of at least 27.5 kg/m",

author = "K.S. Courneya and J. Vardy and S. Gill and D. Jonker and P. O'Brien and C.M. Friedenreich and H. Dhillon and R.K.S. Wong and R.M. Meyer and J.J. Crawford and K.L. Campbell and H. Prapevessis and C. O'Callaghan and J. Turner and L.M. Spencer and {van der Ploeg}, H.P. and D. Tu and C.M. Booth",

year = "2014",

doi = "https://doi.org/10.1007/s11888-014-0231-8",

language = "English",

volume = "10",

pages = "321--328",

journal = "Current colorectal cancer reports",

issn = "1556-3790",

publisher = "Springer Science + Business Media",

number = "3",

}

Courneya, KS, Vardy, J, Gill, S, Jonker, D, O'Brien, P, Friedenreich, CM, Dhillon, H, Wong, RKS, Meyer, RM, Crawford, JJ, Campbell, KL, Prapevessis, H, O'Callaghan, C, Turner, J, Spencer, LM, van der Ploeg, HP, Tu, D & Booth, CM 2014, 'Update on the Colon Health and Life-Long Exercise Change Trial: A Phase III Study of the Impact of an Exercise Program on Disease-Free Survival in Colon Cancer Survivors', Current colorectal cancer reports, vol. 10, no. 3, pp. 321-328. https://doi.org/10.1007/s11888-014-0231-8

TY - JOUR

T1 - Update on the Colon Health and Life-Long Exercise Change Trial: A Phase III Study of the Impact of an Exercise Program on Disease-Free Survival in Colon Cancer Survivors

AU - Courneya, K.S.

AU - Vardy, J.

AU - Gill, S.

AU - Jonker, D.

AU - O'Brien, P.

AU - Friedenreich, C.M.

AU - Dhillon, H.

AU - Wong, R.K.S.

AU - Meyer, R.M.

AU - Crawford, J.J.

AU - Campbell, K.L.

AU - Prapevessis, H.

AU - O'Callaghan, C.

AU - Turner, J.

AU - Spencer, L.M.

AU - van der Ploeg, H.P.

AU - Tu, D.

AU - Booth, C.M.

PY - 2014

Y1 - 2014

N2 - The Colon Health and Life-Long Exercise Change (CHALLENGE) trial is evaluating the effects of a 3-year exercise program on disease-free survival in 962 patients with resected high-risk stage II or stage III colon cancer. The purpose of this commentary is to provide an update on the CHALLENGE trial. As of December 31, 2013, the trial had randomized 250 patients in 20 Canadian centers and 26 Australian centers, with further expansion planned. Early barriers to accrual are reported and strategies to improve accrual are discussed. Of the 250 patients randomized to date, 89 % have stage III colon cancer, 56 % were treated with leucovorin/5-fluorouracil/oxaliplatin-based chemotherapy, 58 % have a body mass index of at least 27.5 kg/m

AB - The Colon Health and Life-Long Exercise Change (CHALLENGE) trial is evaluating the effects of a 3-year exercise program on disease-free survival in 962 patients with resected high-risk stage II or stage III colon cancer. The purpose of this commentary is to provide an update on the CHALLENGE trial. As of December 31, 2013, the trial had randomized 250 patients in 20 Canadian centers and 26 Australian centers, with further expansion planned. Early barriers to accrual are reported and strategies to improve accrual are discussed. Of the 250 patients randomized to date, 89 % have stage III colon cancer, 56 % were treated with leucovorin/5-fluorouracil/oxaliplatin-based chemotherapy, 58 % have a body mass index of at least 27.5 kg/m

U2 - https://doi.org/10.1007/s11888-014-0231-8

DO - https://doi.org/10.1007/s11888-014-0231-8

M3 - Article

SN - 1556-3790

VL - 10

SP - 321

EP - 328

JO - Current colorectal cancer reports

JF - Current colorectal cancer reports

IS - 3

ER -